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We have generated fusion proteins between vascular endothelial growth factor (VEGF) and the bacterial enzyme carboxypeptidase
G2 (CPG2) that can activate the prodrug 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA). Three
asparagine residues of CPG2 were mutated to glutamine (CPG2(Q)3) to prevent glycosylation during secretion, and truncations of
VEGF165 were fused to either the C- or N-terminal of CPG2. The Km of the fusion proteins (37.5mM) was similar to that of secreted
CPG2(Q)3 (29.5mM) but greater than that of wild-type CPG2 (8mM). The affinity of the fusion proteins for VEGF receptor-2
(VEGFR2) (Kd¼0.5–1.1nM) was similar to that of [
125I]VEGF (Kd¼0.5nM) (ELISA) or slightly higher (Kd¼1.3–9.6nM) (competitive
RIA). One protein, VEGF115-CPG2(Q)3-H6, possessed 140% of the enzymic activity of secreted CPG2(Q)3, and had a faster half-
maximal binding time for VEGFR2 (77s), than the other candidates (330s). In vitro, VEGF115-CPG2(Q)3-H6 targeted CMDA
cytotoxicity only towards VEGFR-expressing cells. The plasma half-life of VEGF115-CPG2(Q)3-H6 in vivo was 3h, comparable to
equivalent values observed in ADEPT. We conclude that enzyme prodrug therapy using VEGF as a targeting moiety represents a
promising novel antitumour therapy, with VEGF115-CPG2(Q)3-H6 being a lead candidate.
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Neoangiogenesis is critical for the growth, malignant progression,
and metastatic spread of solid tumours and is effected by the
release of angiogenic factors that are secreted by tumour cells
(Fidler and Ellis, 1994; Folkman, 1995; Fukumura et al, 1998). One
such angiogenic factor is vascular endothelial growth factor
(VEGF) (Tischer et al, 1989). VEGF homodimers act by binding
to two cell surface receptors (VEGFRs), known variously as
VEGFR-1, flt-1, or fms-like tyrosine kinase, and VEGFR2, KDR,
kinase insert domain-containing receptor, or flk-1. Alternate
splicing of the VEGF transcript results in the expression of five
isoforms of VEGF, comprising molecules consisting of 208, 189,
165, 145, or 121 amino acids (Leung et al, 1989; Tischer et al, 1989;
Houck et al, 1991; Poltorak et al, 1997). Of these, only the three
smallest variants, VEGF165, VEGF145, and VEGF121, are secreted as
soluble factors. Cell-surface-associated heparin-like molecules
enhance the binding of VEGF to its receptors. Of the three soluble
variants, VEGF165 and VEGF145 contain such heparin-binding
domains whereas VEGF121 does not.
VEGFRs are highly expressed in areas of neoangiogenesis, such
as in the endothelial cells of tumour vasculature, a restricted
distribution that may be exploited to provide targeted therapy,
using VEGF as a delivery molecule. Fusion proteins between VEGF
and diphtheria toxin are indeed toxic to endothelial cells and to
Kaposi’s sarcoma cell lines, and inhibit angiogenesis, in a VEGFR-
dependent manner (Arora et al, 1999). However, the disadvantage
of such systems is that each protein molecule can affect only one
cell. An alternative to diphtheria toxin is the use of an enzyme that
can convert large numbers of molecules of a low molecular weight
noncytotoxic prodrug to a cytotoxic drug. We have tested whether
the bacterial enzyme carboxypeptidase G2 (CPG2, glutamate
carboxypeptidase, E.C.3.4.17.11) can be fused to VEGF, to deliver
a prodrug-activating enzyme to proliferating endothelial cells.
CPG2 hydrolyses several aromatic N-substituted glutamates to
release benzoic acid, phenol, and aniline mustards (Springer, 1993;
Springer et al, 1995); or when employing a self-immolative
mechanism, can release other conventional therapeutic agents,
such as anthracycline antibiotics (Niculescu-Duvaz et al, 1999). In
this study, we used the noncytotoxic prodrug CMDA that releases
L-glutamic acid and benzoic acid nitrogen mustard, a potent DNA-
alkylating agent (Figure 1). An advantage of alkylating agents is
that they are cytotoxic to both cycling and noncycling cells (Frei
et al, 1988; Teicher and Frei, 1988), such as would be found in
tumours. CPG2 has previously been used in antibody-directed
enzyme-prodrug therapy (ADEPT) in which it is targeted to
tumours with tumour-specific antibodies (Bagshawe, 1990), an
approach in clinical trial (Bagshawe et al, 1991; Napier et al, 2000).
Similarly, expression of CPG2 tethered to the cell surface in gene-
directed enzyme-prodrug therapy (GDEPT) leads to extracellular
prodrug activation (Marais et al, 1997), which in preclinical studies
has been shown to generate a bystander effect, where neighbouring
cells that do not express CPG2 are also killed (Stribbling et al,
2000). By analogy with ADEPT and GDEPT, VEGF-directed
delivery of CPG2 will activate CMDA external to the cells and
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sshould also lead to killing of both target and bystander cells. The
targeting of CPG2 to a tumour using VEGF will also cause
destruction of the tumour vasculature and thus lead to significant
levels of collateral damage with consequent ischaemic death of the
tumour.
In this paper, we describe the construction, expression, and
characterisation of a number of fusion proteins between VEGF and
CPG2 that can bind to recombinant VEGFR2, and can differentiate
between human umbilical vein endothelial cells (HU-V-EC) that
express VEGFR2 and human ovarian adenocarcinoma cells (SK-
OV-3) that do not. Once bound, these proteins can convert CMDA
to its toxic drug derivative and thereby kill the targeted cells.
Further, we identify one construct, VEGF115-CPG2(Q)3-H6, with a
combination of features that recommend it as a lead molecule for
this targeted therapy, which we call Ligand-Directed Enzyme
Prodrug Therapy or LiDEPT.
MATERIALS AND METHODS
Construction of plasmids encoding fusion proteins
All fusion genes were generated by PCR (Ho et al., 1989) and their
sequences verified by automated DNA sequencing. For mamma-
lian expression, constructs were cloned into the vector pEFPlink.2,
which uses the elongation factor 1a (EF1a) promoter to direct
expression in mammalian cells (19). For stable expression, the
vector pMCEF  was used, which also uses the EF1a promoter to
direct expression, but additionally incorporates a neo
R gene for
clone selection (Marais et al, 1997).
Expression and purification of fusion proteins
Mammalian cells were transfected with expression plasmids using
LipofectAmine, as previously described (Marais et al., 1997).
Expression in insect cell vectors was achieved using the
BaculoGold system (Pharmingen) as previously described (Marais
et al, 1997). For small-scale protein extraction, detergent-soluble
extracts were prepared as previously described (Marais et al, 1996),
except that b-mercaptoethanol was omitted from all the buffers.
For bulk protein production, 10
8 Sf9 insect cells were infected with
fusion protein-encoding virus in a total of 100ml growth medium.
The cells were grown in suspension for up to 9 days. Samples of
growth medium (100ml) were monitored daily for CPG2 enzyme
activity. When maximum yield was reached, the conditioned
growth medium was filtered (0.2mm) and dialysed against 3 5l
50mM Tris-HCl pH 8, 500mM NaCl (column loading buffer), and
H6-tagged proteins were purified by nickel-agarose chromato-
graphy, using standard protocols. The proteins were eluted with
loading buffer containing 90mM imidazole, and dialysed exten-
sively against 100mM Tris-HCl pH 7.3, 260mM ZnCl2. The sample
was adjusted to 10% final glycerol and stored at  701C. CPG2
enzyme assays were performed using a standard assay. Briefly,
samples containing CPG2 (100ml) were incubated in 900ml 100mM
Tris-HCl pH 7.3, 260mM ZnCl2 containing methotrexate (MTX,
55mM), and activity was determined from the rate at which the
absorbance at 320nm declined. Immunoprecipitations were
performed using standard approaches, using either a CPG2
polyclonal antibody (Hogg et al, 1987) or the 9E10 monoclonal
antibody, which binds to the myc-epitope tag (Evan et al, 1985).
Receptor binding studies and affinity measurements
The apparent affinities of the fusion proteins for VEGFR2 were
estimated by adapting a method of solid-phase immunoassay
(Hogg et al, 1987). To measure the affinity of VEGF for the ligand-
binding domain of VEGFR2, the binding to a construct in which
the kinase domain was deleted (VEGFR2(DKD)m) was determined.
Microtitre plates (96 well) were precoated with the 9E10 antibody
(20mgml
 1) and nonspecific sites were blocked with 3% skimmed
milk powder in phosphate buffered saline (PBS) pH 7.4 containing
0.1% Tween-20 (PBS-T). Detergent extracts containing
VEGFR2(DKD)m were incubated overnight (41C) and the samples
were incubated with [
125I]VEGF (Amersham Biosciences, UK),
followed by three washes with PBS-T and the amount of VEGF
bound was determined by scintillation counting. The binding of
the fusion proteins to VEGFR2(DKD)m was determined as above,
but using an ELISA format. Following binding of VEGFR2(DKD)m
to the antibody-coated microtitre plates, the samples containing
the various fusion proteins were incubated with the complexes and
the amount of fusion protein bound was measured by ELISA using
a rabbit antiserum to CPG2 followed by anti-rabbit horseradish
peroxidase and developed using the tetramethylbenzidine liquid
substrate system (Sigma-Aldrich, UK).
Binding affinities were also estimated using a competitive
displacement radiolabel receptor assay as previously described
(Keyt et al, 1996) but substituting VEGFR2(DKD)m for the KDR-
IgG fusion protein, and using the fusion proteins secreted from
insect cells. The apparent dissociation constant (Kd) for each
fusion protein was estimated from the concentration required for
50% inhibition of binding of [
125I]VEGF to immobilised
VEGFR2(DKD)m.
Synthesis of CMDA
CMDA prodrug was synthesised as described previously (Springer,
1993). It was prepared as a 100mM solution in DMSO immediately
prior to use.
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Figure 1 Activation of CMDA by CPG2. CPG2 cleaves the benzoic acid
mustard prodrug 4-([2-chloroethyl][2-mesyloxyethyl]amino)benzoyl-L-glu-
tamic acid (CMDA) to release L-glutamic acid and the mustard drug 4-([2-
chloroethyl][2-mesoxyethyl]amino)benzoic acid, a potent DNA-alkylating
agent.
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Human umbilical vein endothelial cells (HU-V-EC) were obtained
from the American Tissue Culture Collection (ATCC) and were
maintained in CS-C medium (Sigma-Aldrich, Missouri, USA),
supplemented with 10% fetal calf serum and endothelial cell
growth factor (Sigma-Aldrich, UK) according to the manufac-
turer’s recommendations. Human ovarian adenocarcinoma SK-
OV-3 cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum.
To determine their inherent sensitivity to CMDA, HU-V-EC and
SK-OV-3 cells were seeded (3 10
5cellswell
 1) in six-well tissue
culture plates. After 2-day growth, the cells were incubated for 19h
with 8000, 4000, 2000, 1000, 500, 250, or 125mM CMDA that had
been diluted in appropriate growth medium. A proportion of the
cells (approximately 30% for HU-V-EC or approximately 3% for
SK-OV-3) were replated and allowed to grow for 5 days, when the
surviving fraction was determined from the incorporation of
[
3H]thymidine (0.4mCiml
 1, 6h).
For LiDEPT-dependent killing of the different cell lines,
confluent monolayers of cells were exposed to varying concentra-
tions of fusion proteins in complete growth medium (371C,
30min), followed by three washes with growth medium to remove
unbound protein. The cells were then incubated in growth medium
containing different concentrations of CMDA (19h) and cell
survival determined as described above.
In vivo stability studies
All experiments were conducted in accordance with the United
Kingdom Co-ordinating Committee on Cancer Research guidelines
(Workman et al., 1998). A group of 18 BALB/C nude mice was
injected i.p. with 50 units of VEGF115CPG2(Q)3-H6 in 200ml PBS.
At intervals of 4, 8, 12, 16, 20, 24h after injection, triplicate blood
samples were collected, and the CPG2 enzymic activity in the
samples determined by assay against the model substrate
methotrexate as previously described (Stribbling et al, 1997)
RESULTS
Construction of fusion proteins between VEGF and CPG2
Since CPG2 is a highly versatile protein, two classes of fusion
protein between VEGF and CPG2 were considered. VEGF was
fused either to the N-terminus or to the C-terminus of CPG2. For
these studies, the aim was for these proteins to be secreted, so that
the structurally important disulphide bonds of VEGF could form
with high efficiency in the oxidising environment of the
endoplasmic reticulum, and for glycosylation of VEGF to occur.
Therefore, all constructs were provided with signal peptides. For
those fusions in which VEGF was fused to the N-terminus of CPG2,
the VEGF signal peptide was employed. For those fusion proteins
that had CPG2 in the N-terminal position, the c-erbB2 signal
peptide was employed, as this approach was previously shown to
direct CPG2 to mammalian secretory pathways (Marais et al,
1997). However, since CPG2 becomes glycosylated and conse-
quently is inactivated in this pathway, a version of CPG2
(CPG2(Q)3) was used, in which all three glycosylation sites were
mutated to prevent this event. The VEGF and CPG2(Q)3 were
separated by either a nine amino-acid linker (EF(G)5TA) or a
minimal linker (GS). A schematic diagram of the various
constructs is shown in Figure 2, and a description of their
amino-acid structures is provided in Table 1. The final four C-
terminal amino acids of VEGF165 were deleted in VEGF161-
CPG2(Q)3-H6 since they contain three positively charged residues,
which, if incorporated between fused VEGF and CPG2(Q)3
moieties, might be subject to recognition and cleavage by serine
proteases such as trypsin. VEGF109 arose accidentally as a PCR-
generated truncation of VEGF165, and was retained for study.
VEGF115 was generated as a refinement of VEGF109, being
truncated exactly at the junction of the heparin-binding domain.
Finally, to facilitate purification, polyhistidine tags (H6) were fused
to the C-termini of a number of the constructs to allow purification
by nickel-agarose chromatography. The observed relative masses
of the constructs were determined from their electrophoretic
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Figure 2 Schematic representations of the structures of CPG2(Q)3-H6
and fusion proteins. SPerb and SPv: signal peptides of c-erb B2 and VEGF,
respectively. CPG2 23-415: amino acids 23–415 of CPG2, showing the
relative positions of the three asparagine to glutamine mutations (Q)
required to avoid glycosylation and concomitant loss of CPG2 activity. H6:
oligohistidine tag for purification by nickel-agarose chromatography.
VEGF165, VEGF109, VEGF115, and VEGF161: amino acids 1–165, 109, 115,
and 161, respectively, of VEGF165. Black box: the relative position of the
heparin-binding sequences of the longer forms of VEGF.
Table 1 Structures of the fusion proteins
Protein Predicted primary sequence Mr (e) Mr (o)
CPG2(Q)3-H6 (c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(H)6AS 43731 45000
CPG2(Q)3-VEGF165 (c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(G)5TA-(VEGF aa 1-165) 62272 59–61000
CPG2(Q)3-VEGF161-H6 (c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(G)5TA-(VEGF aa 1-161)-EF(H)6AS 63215 60–62000
CPG2(Q)3-VEGF109 (c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(G)5TA-(VEGF aa 1-109) 55657 53–55000
CPG2(Q)3-VEGF109-H6 (c-erb B2 aa 1-27)-GS-(CPG2(Q)3 aa 23-415)-EF(G)5TA-(VEGF aa 1-109)-EF(H)6AS 57135 54–59000
VEGF161-CPG2(Q)3-H6 (VEGF aa -26-161)-GS-(CPG2(Q)3 aa 23-415)-EF(H)6AS 61710 61–63000
VEGF115-CPG2(Q)3-H6 (VEGF aa -26-115)-GS-(CPG2(Q)3 aa 23-415)-EF(H)6AS 56386 55–61000
Sequences of linkers between VEGF and CPG2-derived moieties and of oligohistidine tags for purification by nickel-agarose chromatography are given in the one-letter amino-
acid code (22); Mr (e), expected relative subunit molecular weight; Mr (o), observed subunit molecular weight; aa, amino acids. c-erb B2 aa 1–27 encode the c-erb B2 signal
peptide. VEGF aa -26-1 encode the VEGF signal sequence.
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smobilities (Table 1). In each case, the relative mass was similar to
the value that would be predicted from the primary sequence.
Expression and characterisation of VEGF-CPG2 fusion
proteins in mammalian cells
As a first step, CPG2(Q)3-VEGF165, CPG2(Q)3-VEGF109, and
CPG2(Q)3-H6 were transiently expressed (see Table 1, Figure 2)
in COS-7 cells. The filtered, conditioned growth media from the
cells was tested for CPG2 activity, by examining its ability to
hydrolyse the CPG2 substrate methotrexate (MTX). As expected,
CPG2 activity was detected in the conditioned growth medium
from CPG2(Q)3-VEGF165, CPG2(Q)3-VEGF109, and CPG2(Q)3-H6
expressing cells, but not from control cells expressing b-
galactosidase (b-gal)(Figure 3A). There was also detectable CPG2
activity in detergent extracts from these cells (Figure 3A). In
Western blotting of the conditioned medium, CPG2 fusion
proteins were not detected (data not shown). However, fusion
proteins of the expected sizes (see Table 1) were detected in
immunoprecipitates of the conditioned medium that used a CPG2
specific antibody to capture the secreted CPG2-fusion proteins
(Figure 3B, lanes 2–4). The VEGF moieties of the fusion proteins
were then examined for binding to heparin. Conditioned medium
from the cells was incubated with heparin-Sepharose, and the
heparin-bound proteins were analysed by Western blotting. As
expected, only CPG2(Q)3-VEGF165 bound to heparin-Sepharose
(Figure 3C, lane 3), because CPG2(Q)3-VEGF109 does not contain
the heparin-binding domain (Figure 3c, lane 4). b-gal and
CPG2(Q)3-H6 also failed to bind to heparin (Figure 3C, lanes 1,2).
Next, the expression of the additional fusion proteins was tested.
VEGF161-CPG2(Q)3-H6 and VEGF115-CPG2(Q)3-H6 are also se-
creted and accumulate in growth medium to higher levels than the
fusions with the N-terminal CPG2(Q)3 moiety (Table 2). In all
cases, the secreted product accumulates to greater amounts in the
medium than in the cell extracts (Table 2). VEGF115-CPG2(Q)3-H6
is secreted particularly efficiently, with over 98% of the total
expressed activity found in the growth medium. This protein is
also the most highly expressed of all the CPG2-VEGF fusion
proteins tested. To estimate the specific activity of the CPG2
moiety of the fusion proteins, the concentrations of CPG2 protein
in the conditioned media were measured using quantitative
Western blotting. The specific activities of the different fusion
proteins could then be estimated using the standard enzyme assay.
All of the fusion proteins had levels of enzyme activity equivalent
to, or higher than the nonfused secreted form of CPG2(Q)3
(CPG2(Q)3-H6; Table 2). Indeed, the fusions with the shorter forms
of VEGF both had greater activity (approximately 140%) than
secreted CPG2(Q)3. However, there does not appear to be any
difference in CPG2 activity when the relative orientation of the
VEGF- and CPG2-derived moieties is compared. Quantitative
Western blotting was also used to determine the relative efficiency
of binding of the fusion proteins to heparin-Sepharose as in
Table 2. CPG2(Q)3-VEGF165 and VEGF161-CPG2(Q)3-H6 both
bound to heparin with similar efficiencies, whereas the binding
of the fusions with the shorter forms of VEGF was severely reduced
(Table 2).
1.00
0.75
0.50
0.25
0.00
A
3
2
0
 
(
n
m
)
0 25 50 75100125
Time (min)
-220-
-97.4-
- 66 -
- 46 -
1234 1234

-
G
A
L
C
P
G
2
(
Q
)
3
-
H
6
C
P
G
2
(
Q
)
3
-
V
E
G
F
1
6
5
C
P
G
2
(
Q
)
3
-
V
E
G
F
1
0
9

-
G
A
L
C
P
G
2
(
Q
)
3
-
H
6
C
P
G
2
(
Q
)
3
-
V
E
G
F
1
6
5
C
P
G
2
(
Q
)
3
-
V
E
G
F
1
0
9
AB C
Figure 3 Expression of VEGF-CPG2 fusion proteins in mammalian cells.
(A) CPG2 enzyme activity assays. COS-7 cells were transiently transfected
with expression constructs for CPG2(Q)3-VEGF165 (m,n), CPG(Q)3-
VEGF109 (~,}), CPG2(Q)3-H6 (K,J) and b-galactosidase (’, &).
CPG2 enzyme assays were performed on B1/30th of the conditioned
growth medium (100ml; n,},&,J) or detergent cell extracts (B10mgo f
protein; m,~,’,K). Data are means of three separate transfections,
except for b-galactosidase expression, which are mean data from two
separate transfections. (B) Western blotting of fusion proteins. Proteins
from the conditioned medium from COS cells expressing b-galactosidase
(b-gal) (lane 1), CPG2(Q)3-H6 (lane 2), CPG2(Q)3-VEGF165 (lane 3), and
CPG(Q)3-VEGF109 (lane 4) were immunoprecipitated using a polyclonal
antibody to CPG2 and subjected to Western blotting for fusion protein
expression. The positions of migration of size markers ( 10
 3) are shown
to the right and arrowheads to the left identify the proteins as follows:
upper, CPG2(Q)3-VEGF165, middle CPG2(Q)3-VEGF109, and lower,
CPG2(Q)3-H6. The figure is a composite of two separate segments of
one gel. (C) Heparin binding of VEGF-CPG2 fusion proteins. Conditioned
medium from COS-7 cells transiently expressing b-gal (lane 1), CPG2(Q)3-
H6 (lane 2), CPG2(Q)3-VEGF165 (lane 3), and CPG2(Q)3-VEGF109 (lane
4) was analysed for the ability of the fusion proteins to bind to heparin-
Sepharose. Western blotting revealed the bound proteins and the positions
of migration of size markers ( 10
 3) are shown to the left. The
arrowhead to the right points towards the position of migration of
CPG2(Q)3-VEGF165. The figure is a composite of two separate segments
of one gel.
Table 2 Expression of fusion proteins between CPG2(Q)3 and VEGF in COS-7 cells
Total CPG2 activity (Uwell
 1) in:
Relative CPG2-specific Relative heparin-binding
Protein Cells Medium activity (%) activity (%)
CPG2(Q)3-VEGF165 0.0023 (70.0005) 0.021 (70.001) 110 (711) 100
CPG2(Q)3-VEGF109 0.0077 (70.0005) 0.023 (70.001) 143 (713) 2.1
VEGF161-CPG2(Q)3-H6 0.0098 (70.0013) 0.037 (70.009) 102 (713) 99
VEGF115-CPG2(Q)3-H6 0.0009 (70.0001) 0.066 (70.011) 140 (719) 10.2
CPG2(Q)3-H6 0.084 (70.10) 0.139 (70.004) 100 2.4
The CPG2 in conditioned media and cell extracts was measured using quantitative Western blotting to estimate the relative protein levels by phosphorimaging. The relative
activity of the different fusion proteins could then be estimated using the standard enzyme assay. Quantitative Western blotting was also used to determine the relative efficiency
of binding of the fusion proteins to heparin-Sepharose. Data shown for measurements of total activity and relative activity are means (7s.d.) of three transfections.
Ligand-directed tumour endothelial cell kill
RA Spooner et al
1625
British Journal of Cancer (2003) 88(10), 1622–1630 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sExpression of VEGF-CPG2 fusion proteins in Sf9 cells
The above data establish that CPG2-VEGF fusion proteins can be
produced that retain CPG2 enzyme activity and heparin binding in
the VEGF moiety. These fusion proteins were tested for binding to
the VEGF receptor, VEGFR2, to ascertain whether they could
mediate killing of mammalian cells. To perform these experiments,
large amounts of fusion protein were expressed in Sf9 insect cells.
Baculoviruses encoding CPG2(Q)3-H6, VEGF115-CPG2(Q)3-H6,
CPG2(Q)3-VEGF109-H6, and VEGF161-CPG2(Q)3-H6, were gener-
ated and used to infect Sf9 insect cells. The fusion proteins were
purified from conditioned growth media by single-step nickel-
agarose affinity chromatography, and were judged to be 99% pure
by silver staining (data not shown) except for VEGF161-CPG2(Q)3-
H6, which required an extra heparin affinity chromatography step
to reach a similar degree of purity (data not shown).
CPG2 is a homodimeric protein that is denatured by heat
treatment in the presence of SDS, and so migrates as monomers in
polyacrylamide gels following heat treatment (Spooner et al, 2000).
VEGF is also a homodimer, but it is stabilised by disulphide
linkage. To assess whether the VEGF moieties were stabilised by
disulphide linkages, the different fusion proteins were subjected to
heat treatment under reducing or nonreducing conditions. As
expected, CPG2(Q)3-H6 migrated as a monomer under both
reducing and nonreducing conditions (Figure 4, lanes 1, 5).
VEGF115-CPG2(Q)3-H6, CPG2(Q)3-VEGF109-H6, and VEGF161-
CPG2(Q)3-H6 also migrated as monomers under reducing condi-
tions (Figure 4, lanes 2–4), but under nonreducing conditions
migrated with sizes that were consistent with dimerization
(Figure 4, lanes 6–8). A contaminating protein, presumably a
degradation product related to CPG2, is routinely found in
preparations of VEGF161-CPG2(Q)3-H6 (Figure 4, lanes 4, 8). We
conclude that the VEGF moieties in these fusion proteins are
stabilised by disulphide linkages. These fusion proteins were then
tested for the ability to bind to the ligand-binding domain of
VEGFR2. For these studies, the extracellular and transmembrane
domains of VEGFR2 were expressed as a 9E10-tagged protein in
insect cells. This construct, which has the kinase domain (KD) of
VEGFR2 deleted, included codons  20–809 of VEGFR2 fused to a
9E10 monoclonal antibody epitope (VEGFR2(DKD)m).
For VEGF binding studies, VEGFR2(DKD)m in a 96-well plate
ELISA format was used. The plates were seeded with the 9E10
monoclonal antibody and VEGFR2(DKD)m was captured on the
immobilised 9E10 antibody. [
125I]VEGF bound to this immobilised
VEGFR2(DKD)m with high affinity (KdB0.5nM). The fusion
proteins were incubated with the captured VEGFR2(DKD)m and
binding was determined. All of the fusion proteins bound with
similar affinities, with Kd values of approximately 0.5–1.1nM
(Figure 5A, Table 3).
A competition RIA was used where binding of [
125I]VEGF to
VEGFR2(DKD)m occurs in the presence of competing fusion
proteins. Using this analysis, the binding of the fusion proteins was
estimated to be slightly higher, with Kd values from 1.3–9.6nM
(Figure 5B, Table 3). CPG2(Q)3-H6 protein did not compete for
[
125I]VEGF binding in this assay (Table 3). Finally, the rate of
binding was measured, by exposing the fusion proteins to
immobilised VEGFR2(DKD)m for short times before washing out
the protein and measuring how much fusion protein was bound.
VEGF115CPG2(Q)3-H6 reaching half-maximal binding in 77s
(Figure 5C, Table 3). The binding of CPG2(Q)3VEGF109-H6 and
VEGF161CPG2(Q)3-H6 was somewhat slower, reaching half-max-
imal binding after about 330s.
Kinetic analysis of VEGF115CPG2(Q)3-H6
Taken together, the above data suggest that VEGF115CPG2(Q)3-H6
is the most suitable candidate for the LiDEPT approach. It displays
rapid binding to receptor, is secreted efficiently, is the most highly
expressed, and has the highest specific activity. We therefore
subjected this protein to detailed kinetic analysis for the CPG2
activity. CPG2 produced in bacteria has a Km for MTX of 8mM
(Sherwood et al, 1985). Similarly, CPG2 expressed in the cytosol of
mammalian and insect cells also have Km values for MTX of
approximately 7mM (Napier et al, 2000). Secreted CPG2(Q)3-H6,
has a Km of 29.5mM MTX and VEGF115-CPG2(Q)3-H6 a Km of
37.5mM MTX (mean of two independent preparations). Again, a
slight increase in catalytic activity was noted for this fusion protein
(140%, Table 2). Thus, the fusion of VEGF domains to CPG2(Q)3
does not appear to affect the affinity for substrate as compared to
secreted CPG2(Q)3, and can result in a moderate increase in
catalytic activity.
Fusion proteins of CPG2 and VEGF can direct cytotoxicity
to VEGFR2-positive cells
VEGF-CPG2 fusion proteins were next assessed for their ability to
generate a targeted increase in the cytotoxicity of CMDA towards
HU-V-EC cells, which express receptors for VEGF. Initially, the
sensitivity of HU-V-EC cells to CMDA alone was established. The
IC50 of CMDA in HU-V-EC cells was 1587 (7) 224mM (Figure 6A).
The highest dose of CMDA that produced no cytotoxicity in HU-V-
EC cells was 500mM (open arrowhead, Figure 6A).
Confluent HU-V-EC cells were incubated with three doses of
VEGF115-CPG2(Q)3-H6, CPG2(Q)3-VEGF109-H6, or CPG2(Q)3-H6
(50, 5, or 0.5nM) in complete growth medium for 30min, after
which the unbound proteins were removed by rinsing  3. These
cells were then incubated in the previously established nontoxic
dose of CMDA (500mM), and cell survival then determined in our
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Figure 4 VEGF-CPG2(Q)3 and CPG2(Q)3-VEGF fusion proteins are
disulphide-linked dimers. Affinity-purified CPG2(Q)3-H6, VEGF115-
CPG2(Q)3-H6, CPG2(Q)3-VEGF109-H6, and VEGF161-CPG2(Q)3-H6
proteins were heated in either reducing (lanes 1– 4) or nonreducing
(lanes 5–8) conditions, subjected to polyacrylamide gel electrophoresis
and were identified after immunoblotting using a rabbit anti-CPG2 serum
and
125I-Protein A. Closed arrowheads show the positions of migration of
monomers and open arrowheads show the positions of migration of
dimers. The positions of migration of size markers ( 10
 3) are shown to
the right. Asterisks mark the positions of migration of a breakdown product
derived from VEGF161-CPG2(Q)3-H6 protein.
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sstandard assay. Only a slight increase in cytotoxicity was seen with
increasing concentrations of CPG2(Q)3-H6 (Figure 6B). By
contrast, a marked protein-dose-dependant reduction in survival
was seen following exposure to VEGF115-CPG2(Q)3-H6, and
VEGF109-CPG2(Q)3-H6, indicative of these proteins having resisted
rinsing, being bound, presumably to the VEGFRs of the cells. To
confirm that this increased cytotoxicity is indeed the result of
binding to VEGFRs, a similar experiment was performed,
comparing HU-V-EC cells to SK-OV-3 cells, which by contrast
do not express VEGFRs. As previously, the sensitivity to CMDA
alone was first established. The IC50 of CMDA in SK-OV-3 cells was
4323 (7473)mM (Figure 6A) very similar to our previous estimate
(Marais et al, 1997). The highest dose of CMDA that produced no
cytotoxicity in SK-OV-3 cells was 1000mM (filled arrowhead,
Figure 6A). HU-V-EC and SK-OV-3 cells were treated with 50nM
VEGF115-CPG2-H6, washed three times, and then treated with
subcytotoxic doses of CMDA (500 and 1000mM, respectively). This
results in an increase in cytotoxicity (75%) in HU-V-EC cells, but
not in SK-OV-3 cells (Figure 6), confirming that the fusion protein
is binding to VEGFRs on HU-V-EC cells.
Thus, the cytotoxic drug is being generated from concentrations
of CMDA similar to those achieved in the plasma of human
patients during a phase I/II ADEPT clinical trial (Martin et al,
1997).
Stability of fusion protein in vivo
When VEGF115-CPG2-H6 was injected i.p. into mice, the plasma
levels of enzymic CPG2 activity decayed with a one-phase
exponential half-life of 3h (Figure 7), similar to that previously
observed (4h) with an antibody fragment-CPG2 conjugate, known
as A5B7-F(ab’)2-CPG2, used in ADEPT (Sharma et al, 1990). The
presence of enzymic activity implies the presence of intact dimers,
and we anticipate that this stability in the circulation will also allow
localisation similar to that seen in ADEPT (Napier et al, 2000), a
therapy now in phase I/II trial.
DISCUSSION
The approach of targeting cytotoxicity via a fusion protein has a
long and successful history. Prime examples are the fusions of cell-
binding ligands with the catalytic subunit of Pseudomonas
exotoxin A, which lacks cell-binding activity. The first example
was fusion with transforming growth factor-type alpha (Chaudh-
ary et al, 1987). Since then, a wide range of fusion partners have
been considered, including interleukins (Chaudhary et al, 1989;
Batra et al, 1991, 1992; Kreitman et al, 1992; Gawlak et al, 1993;
Kunwar et al, 1993; Francisco et al, 1995; Siegall et al, 1995), other
growth factors (Prior et al, 1991; Gawlak et al, 1993; Kunwar et al,
1993; Mesri et al, 1993; Siegall et al, 1995), single chain antibody
fragments (Chaudhary et al, 1989; Batra et al, 1991, 1992; Kreitman
et al, 1992; Francisco et al, 1995) and hormones (Ben Yehudah et al,
1999). Such studies have demonstrated that a wide range of ligands
can be regarded as potential antitumour-targeting devices, and a
wide range of cellular receptors can be viewed as targets.
Furthermore, complete regressions have been recorded (Brink-
mann et al, 1991), underlining the success of this approach.
We considered the VEGFRs as targets for an approach to deliver
not a toxin, but an enzyme with catalytic activity capable of
converting large numbers of molecules of a nontoxic prodrug to a
toxic drug. We show that VEGF-CPG2 fusion proteins retain
activities of both parental molecules, irrespective of whether they
are the N- or C-terminal moiety, and that they retain these
characteristics if either very short or longer linkers are used to join
them. If provided with either the VEGF signal sequence or the c-
erb B2 signal sequence, all the fusions are secreted into the growth
medium, from where they could be purified to near homogeneity
by single-step nickel-agarose chromatography. All the fusions are
disulphide-linked dimers as expected. Those with shorter VEGF
moieties show a moderate (1.4-fold) increase in CPG2 activity.
Native CPG2 is active as a dimeric protein, while CPG2(Q)3 has a
comparatively reduced activity owing to a reduction in dimer
stability (Spooner et al, 2000). It is therefore possible that fusion
with the shorter forms of VEGF compensates for the deleterious
effect of the (Q)3 mutations by improving dimer stability. These
fusion proteins bind VEGFR2 domains with an affinity close to
that of VEGF, and one in particular, VEGF115-CPG2(Q)3-H6
binds very rapidly. It retains specificity for VEGFR2, and can
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Figure 5 In vitro binding assays: (A) ELISA showing binding of [
125I]VEGF
(K), VEGF115-CPG2(Q)3-H6 (n), VEGF161-CPG2(Q)3-H6 (&),or
CPG2(Q)3-VEGF109-H6 (}) to VEGFR2(DKD)m. (B) RIA showing
competition of CPG2(Q)3-H6 (J), VEGF115-CPG2(Q)3-H6 (n),
VEGF161-CPG2(Q)3-H6 (&), CPG2(Q)3-VEGF109-H6 (}), or VEGF165
(K) with [
125I]VEGF for VEGFR2(DKD)m. (C) Kinetics of binding of
VEGF115-CPG2(Q)3-H6 (n),VEGF161-CPG2(Q)3-H6 (&),or CPG2(Q)3-
VEGF109-H6 (}) to VEGFR2(DKD)m captured by immobilised 9E10
monoclonal antibody, measured by ELISA.
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sdifferentiate between endothelial cells that express VEGFRs (HU-
V-EC) and those that do not (SK-OV-3). Once delivered to cells,
the proteins can convert the prodrug CMDA to its toxic metabolite,
thus killing targeted cells.
Although expression of VEGFR2 is high in the neoangiogenic
regions of tumour vasculature, some normal organs also express
VEGFRs (Blaauwgeers et al, 1999; Kim et al, 1999). Both receptors
are expressed predominantly in endothelial cells, but a few
additional cell types express one or both of these receptors.
Despite these caveats, recognition of VEGFRs as therapeutic
targets for cancer is likely to be of value. Indeed, VEGF-diphtheria
toxin fusion proteins are toxic to endothelial cells and Kaposi’s
sarcoma cell lines, inhibit angiogenesis and retard tumour growth,
in a VEGFR-dependent manner (6). Since nearly all tumours
induce local angiogenesis with associated high levels of VEGFR
expression, VEGF-derived targeting molecules may have wide
application for therapy.
VEGF-CPG2 fusion proteins should direct CPG2 activity to cells
expressing VEGFRs, principally those activated endothelial cells in
tumour vasculature. Once localised, these proteins can convert a
nontoxic prodrug into a cytotoxic drug, thus providing targeted
cell death of tumour neovasculature. Such a strategy might be
expected to lead to cell death of targeted cells, plus a ‘bystander’
component of neighbouring nontargeted cells killed by high
concentrations of soluble drug near the targeted cells, and perhaps
associated with a further bystander effect via ischaemia. Since
halting angiogenesis suppresses carcinoma cell invasion (Skobe
et al, 1997), VEGFR-targeted CPG2 might also reduce spread of the
disease. The features of the VEGF-CPG2 fusion proteins we
describe here suggest that targeted therapy by LiDEPT is a feasible
strategy for the targeting of activated endothelial cells in a tumour.
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Figure 6 Cytotoxicity studies. (A) Sensitivity of HU-V-EC (J) and SK-
OV-3 cells (K) to treatment with the prodrug CMDA. Arrowheads show
the maximum concentrations of CMDA that the HU-V-EC (,) and SK-
OV-3 cells (.) cells can tolerate without measurable cell death. (B) Effect
on the survival of HU-V-EC cells of preincubation with CPG2(Q)3-H6,
CPG2(Q)3-VEGF109-H6, or VEGF115CPG2(Q)3-H6, at doses of 0.5nm
(plain bars), 5nm (shaded bars), or 50nm (filled bars) and subsequent
treatment with 500mM CMDA. (C) Sensitivity of HU-V-EC and SK-OV-3
cells to CMDA challenge (500 and 1000mM, respectively) after a 30min
incubation with 50nm VEGF115CPG2(Q)3-H6.
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Figure 7 Balb/c nude mice were injected i.p. with 50U CPG2. At
intervals as indicated, blood was collected and analysed for CPG2 activity.
The line is a fit to a one-phase exponential decay with a half-life of 2.8h.
Each point represents the mean of three separate determinations7s.e.m.
Table 3 Binding characteristics of fusion proteins between CPG2(Q)3 and VEGF expressed in insect cells
Protein ELISA Kd (nM) Competition RIA Kd (nM) 50% binding t50 (s)
CPG2(Q)3-VEGF109-H6 0.75 (70.05) 1.3 (70.1) 332
VEGF161-CPG2(Q)3-H6 1.06 (70.66) 3.3 (70.3) 330
VEGF115-CPG2(Q)3-H6 0.51 (70.08) 9.6 (70.6) 77
CPG2(Q)3-H6 ND No competition ND
[
125I]-VEGF 0.51 (70.06) ND ND
VEGFR2(DKD)m was captured on the 9E10 antibody immobilised in 96-well plates. The fusion proteins were incubated with the captured VEGFR2(DKD)m and binding was
determined. We also used a competition RIA where binding of [
125I]VEGF to VEGFR2(DKD)m occurs in the presence of competing fusion proteins. The rate of binding was also
determined, by exposing the fusion proteins to immobilised VEGFR2(DKD)m for short times before washing out the protein and measuring how much fusion protein was bound.
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sIn summary, we have developed a VEGF115-CPG2(Q)3-H6 fusion
protein that is highly expressed, efficiently secreted, has a high
specific activity, binds rapidly to its target, can direct prodrug
cytotoxicity to VEGFR2-expressing cells, and is a candidate for a
new approach to cancer therapy.
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